People: Sanofi SA (SNY)

Summary

Name	Age	Since	Current Position
Serge Weinberg	61	2010	Chairman of the Board
Christopher Viehbacher	53	2008	Chief Executive Officer, Chairman of the Executive Committee and Global Leadership Team and Director
Jerome Contamine	55	2009	Executive Vice President - Chief Financial Officer, Member of the Executive Committee and Global Leadership Team
David Meeker		2011	Executive Vice President and Chief Executive Officer of Genzyme, Member of the Global Leadership Team
Gary Nabel		2012	Senior Vice President, Chief Scientific Officer and Deputy to the President for Global R&D, Member of the Global Leadership Team
Karen Linehan	54	2012	Member of the Executive Board, Member of the Management Board, Senior Vice President, General Counsel
Roberto Pucci	49	2009	Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
Olivier Charmeil	50	2011	Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Philippe Luscan	51	2008	Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Jose Barella		2011	Senior Vice President - Animal Health and Member of the Global Leadership Team
Damian Braga		2011	Senior Vice President - Vaccines Global Commercial Operations and Member of the Global Leadership Team
Jean-Francois Brin	47	2009	Senior Vice President - Patient Centered Solutions and Member of the Global Leadership Team
Pierre Chancel	55	2009	Senior Vice President - Global Diabetes and Member of the Global Leadership Team
Michel DeWilde		2001	Senior Vice President - R&D Sanofi Pasteur and Member of the Global Leadership Team
Gregory Irace	53	2011	Senior Vice President - Global Services and Member of the Global Leadership Team
Marie-Helene Laimay	53	2004	Senior Vice President - Audit and Internal Control Assessment and Member of the Global Leadership Team
Christian Lajoux	64	2009	Senior Vice President & President Sanofi France, Member of the Global Leadership Team
Gilles Lhernould	56	2009	Senior Vice President - Corporate Social Responsibility and Member of the Global Leadership Team
Jean-Luc Lowinski		2012	Senior Vice President - Asia Region, Vice President, Greater China Global Operations and Member of the Global Leadership Team
Heraldo Marchezini		2011	Senior Vice President - Latin America Region, General Manager - Brazil Global Operations and Member of the Global Leadership Team
Jez Moulding		2011	Senior Vice President - Japan & Pacific Region and General Manager - Japan, Member of the Global Leadership Team
Antoine Ortoli	58	2005	Senior Vice President - Intercontinental Global Operations and Member of the Global Leadership Team
Philippe Peyre	61	2004	Senior Vice President - General Secretary and Member of the Global Leadership Team
Debasish Roychowdhury	50	2009	Senior Vice President - Global Oncology and Member of the Global Leadership Team
Jean-Philippe Santoni	57	2009	Senior Vice President - Industrial Development and Innovation and Member of the Global Leadership Team
Laure Thibaud	53	2009	Senior Vice President - Corporate Communications, and Member of the Global Leadership Team
Paul Chew		2013	Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs and Member of the Global Leadership Team
Bruno Menard		2011	Chief Information Officer and Member of the Global Leadership Team
Dante Beccaria		2012	Vice President, Global Compliance Officer and Member of the Global Leadership Team
Thierry Vernier		2011	Vice President - Plan & Financial Control, Member of the Global Leadership Team
Sebastien Martel		2008	Vice President - Investor Relations and Member of the Global Leadership Team
Francois Beloeuvre			Vice-President - Strategy Industrial Affairs, Member of the Global Leadership Team
Thierry Bourquin		2009	Vice President, Chief Quality Officer and Member of the Global Leadership Team
Jean-Philippe Collin	56	2010	Vice President - Procurement and Member of the Global Leadership Team
Robert DeBerardine		2011	Vice President, Head of Global Patent Department and Member of the Global Leadership Team
Edward Greissing			Vice President - US Corporate Affairs, Global Services; Member of the Global Leadership Team
Jorge Insuasty		2011	Vice President, Deputy of President R&D, Development and Member of the Global Leadership Team
Andrew Plump		2012	Vice President, Research & Translational Medicine and Deputy to the President of Global R&D and Member of the Global Leadership Team
Maya Said		2011	Vice President - Strategy, External Innovation & Science Policy, Global R&D; Member of the Global Leadership Team
Martin Siewert		2008	Vice President Industrial Affairs - Injectables, President - Germany and Member of the Global Leadership Team
Elias Zerhouni	62	2011	President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Dominique Carouge		2011	Vice President - Administration & Management, Global R&D and Member of the Global Leadership Team
Peter Guenter		2013	Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
David-Alexandre Gros	40	2011	Chief Strategy Officer, Member of the Executive Committee and the Global Leadership Team
David Khougazian		2011	Head of the Office of the Chief Executive Officer and Member of the Global Leadership Team
Anne Whitaker		2011	President - North America, Pharmaceuticals and Member of the Global Leadership Team
Ji Zhang		2011	Head of R&D Scientific Platforms and Member of the Global Leadership Team
Laurent Attal	55	2012	Director
Thierry Desmarest	67	2000	Director
Igor Landau	68	2004	Director
Christian Mulliez	52	2004	Director
Uwe Bicker	67	2008	Independent Director
Robert Castaigne	67	2012	Independent Director
Lord Douro	67	2002	Independent Director
Jean-Rene Fourtou	73	2004	Independent Director
Claudie Haignere	56	2008	Independent Director
Suet-Fern Lee	55	2011	Independent Director
Carole Piwnica	55	2010	Independent Director
Klaus Pohle	75	2004	Independent Director
Gerard Van Kemmel	73	2003	Independent Director

» Insider Trading

Biographies

Name	Description
Serge Weinberg	Mr. Serge Weinberg has been Chairman of the Board at Sanofi SA since May 17, 2010. He is also Chairman of the Company's Nominating and Governance Committee as well as of Strategy Committee. Additionally, Mr. Weinberg is also Director of VL Holding, Manager of Alret and Maremma, and Member of the Supervisory Board of Schneider Electric and Financiere BFSA, among others. Previously, he was Director of Sanofi SA from December 16, 2009 until May 17, 2010. He became Chief of Staff of the French Budget Minister, Laurent Fabius, in 1981. After a position of Deputy General Manager for Finance at the French Television Channel FR3 (1982-1983), he became Chief Executive Officer and then Chairman of the Havas Tourisme Group, the function he held from 1983 to 1987. He was then appointed CEO of Pallas Finance for three years and joined the Pinault Group in 1990 as President of CFAO. In the Pinault Group, he was then appointed Chairman and CEO of Rexel for the period from 1991 to 1995 and chaired the Management Board of the PPR Group for 10 years. In March 2005, he founded the investment firm Weinberg Capital Partners, which manages funds dedicated to LBO and real estate. Mr. Weinberg was also Non-Executive Chairman of the Board of the Accor Group from 2006 to 2009. Mr. Weinberg obtained a degree in Law, a Graduate Degree from the Institut d'Etudes Politiques de Paris and obtained a degree from the ENA - Ecole Nationale d'Administration Publique in 1976.
Christopher Viehbacher	Mr. Christopher A. Viehbacher has been Chief Executive Officer, Chairman of the Executive Committee and Global Leadership Team and Director of Sanofi SA as of December 1, 2008. He is also Member of the Company's Strategy Committee and has been President of Genzyme as of April 2011. In addition to that, he has been Chair of the CEO Roundtable on Cancer since February 2011. He also holds other mandates, including Vice Chairman of EFPIA (Belgium) and Member of the International Business Council, World Economic Forum (Switzerland), among others. From December 2010 to 2012, Mr. Viehbacher was Chairman of PhRMA in the United States. After starting his career at PriceWaterhouseCoopers, he spent the major part of his professional life (1988-2008) in the Wellcome group, GlaxoWellcome and then GlaxoSmithKline (GSK) where he held different positions across Europe (Germany, France, and Great Britain) and in the United States and Canada. In its last position, Mr. Viehbacher was President, Pharmaceutical Operations North America, Co-Chairman of the Portfolio Management Board. He was made a knight of the French Legion of Honor in 2003. Mr. Viehbacher obtained a Bachelor of Arts degree in Commerce from the Queens University of Ottawa (Canada) and is a Certified Public Accountant.
Jerome Contamine	Mr. Jerome Contamine has served as Executive Vice President - Chief Financial Officer, Member of the Executive Committee and Global Leadership Team of Sanofi SA as of March 16, 2009. After four years at the Cour des Comptes as a Senior State General Auditor, he joined Elf Aquitaine in 1988, as Advisor to the Chief Financial Officer, and became Group Finance Director & Treasurer in 1991. He became General Manager of Elf Petroleum Norway in 1995, after being named Deputy Vice President of Elf Upstream Division for Europe and the U.S. In 1999, he was appointed Member of the taskforce for integration with Total, in charge of the reorganization of the merged entity, TotalFinaElf, and became, in 2000, Vice President Europe and Central Asia, Upstream Division of Total. The same year, he joined Vivendi Environnement as CFO and Deputy General Manager. In 2003, he became Senior Executive Vice President, Deputy General Manager, Chief Financial Officer of Veolia Environnement and Director of Valeo. Mr. Contamine obtained a degree from the Ecole Polytechnique in 1979 and from the Ecole Nationale de la Statistique et de l'Administration de l'Economie (ENSAE). He also earned a degree from the Ecole Nationale d'Administration in 1984.
David Meeker	Dr. David P. Meeker, M.D., has served as Executive Vice President and Chief Executive Officer of Genzyme, Member of the Global Leadership Team of Sanofi SA, effective as of November 1, 2011. He received his Doctorate of Medicine (M.D.) degree from the University of Vermont Medical School. He completed an Internal Medicine residency at Beth Israel Hospital in Boston and a Pulmonary/Critical Care fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000. Prior to joining Genzyme, he was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr. Meeker, M.D., joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including treatments in the current rare genetic diseases portfolio. He was promoted to Senior Vice President in 1998, and in 2000 became the Business Unit Leader for Genzyme’s Lysosomal Storage Disease and Thyrogen programs in Europe. He was promoted to President of the Global LSD business unit in 2003. In this role, he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. In 2008, he was promoted to Executive Vice President of Therapeutics, Biosurgery and Transplant. In 2009, he became Chief Operating Officer. In this role, he was responsible for Genzyme's commercial organization, overseeing the business units, country management organization and global market access functions.
Gary Nabel	Dr. Gary J. Nabel M.D., Ph.D. has been Senior Vice President, Chief Scientific Officer and Deputy to the President for Global R&D, Member of the Global Leadership Team at Sanofi SA since December 3, 2012. He is also Chairman of the Strategic Development and Scientific Advisory Council (SDSAC). Previously, he worked at the National Institutes of Health (NIH), where he served as Director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases from 1999. He graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard University, completing his Doctorate in Philosophy (Ph.D.) in 1980 and his Doctorate of Medicine (M.D.) in 1982. He served as a postdoctoral fellow in the laboratory of David Baltimore at MIT’s Whitehead Institute. Before his appointment at the Vaccine Research Center, Dr. Nabel M.D., Ph.D. served as the Henry Sewall Professor of Internal Medicine, Professor of Biochemistry, and Howard Hughes Medical Institute Investigator at the University of Michigan in Ann Arbor. In addition to his faculty positions, he also served as Director of the Center for Gene Therapy and Co-Director of the Center for Molecular Medicine at the University of Michigan. He was elected as Member of the Institute of Medicine of the National Academy of Sciences in 1998.
Karen Linehan	Ms. Karen Linehan has been Member of the Executive Board, Member of the Management Board, Senior Vice President, General Counsel of Sanofi SA since April 1, 2012. Previously, she served as Senior Vice President - Legal Affairs and General Counsel, Global Compliance Officer Interim, Member of the Executive Committee and the Global Leadership Team of the Company from 2011 to April 1, 2012. Between March 26, 2007 and 2011, she held the functions of Senior Vice President - Legal Affairs and General Counsel, Member of the Executive Committee and Management Committee of Sanofi SA. Prior to practicing law, Ms. Linehan served on the congressional staff of the Speaker of the U.S. House of Representatives from September 1977 to August 1986. Until December 1990, she was Associate in a law firm in New York, New York. In January 1991, she joined Sanofi as Assistant General Counsel of its US subsidiary. In July 1996, Ms. Linehan moved to Paris to work on international matters within the Group and she has held a number of positions within the Legal Department, most recently as Vice President - Deputy Head of Legal Operations. Ms. Linehan obtained a Bachelor of Arts degree in Literature and a Juris Doctor degree in Law, both from the Georgetown University.
Roberto Pucci	Mr. Roberto Pucci has been Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team at Sanofi SA as of October 2009. He has a degree in Law from the Universite de Lausanne, Switzerland. He started his career in 1985 at Coopers & Lybrand in Geneva, Switzerland as an external auditor. He then joined Hewlett- Packard (HP) in 1987, where he held various positions in Human Resources in Switzerland and Italy including Human Resources Manager for the European Headquarter and Human Resources Director in Italy. In 1999, he became Director, Compensation and Benefits for Agilent Technologies, a spin off from HP, and was appointed Vice President Human Resources Europe in 2003. In 2005 he moved to the United States to join Case New Holland, a subsidiary of the Fiat Group, as Senior Vice President, Human Resources, and was appointed, in 2007, Executive Vice President, Human Resources for the Fiat Group in Torino, Italy.
Olivier Charmeil	Mr. Olivier Charmeil has been Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team of Sanofi SA since January 1, 2011. He joined the Company as Senior Vice President - Pharmaceutical Operations in Asia-Pacific Region on February 1, 2006, the function he held until January 1, 2008, when he became appointed Senior Vice President - Pharmaceutical Operations in Asia Pacific Region and Japan for over one year, until February 2009. From then to January 1, 2011, he served as Senior Vice President - Asia/Pacific & Japan Vaccines, Member of the Management Committee of the Company. From 1989 to 1994, he worked in the Mergers and Acquisitions department of Banque de l’Union Europeenne. He joined Sanofi Pharma in 1994 as Head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Synthelabo in 1999 and Attache to the Chairman, Jean-Francois Dehecq, in 2000, before being appointed as Vice President of Development within the Sanofi-Synthelabo International Operations Division, where he was responsible for China and support functions. In 2003, Mr. Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthelabo France, before taking the post of Senior Vice President of Business Management and Support within the Pharmaceutical Operations Division. Mr. Charmeil obtained a degree from the Hautes etudes commerciales (HEC) and from the Institut d'Etudes Politiques de Paris.
Philippe Luscan	Mr. Philippe Luscan has been Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team of Sanofi SA since September 2008. He previously served as Vice President - Chemistry of the Company from September 2006 to September 2008. He graduated from Ecole Polytechnique and from Ecole des Mines de Paris in Biotechnology. He started his career with Danone in 1987 as Head of Production. He joined the Company in 1990, as Plant Director for Sanofi Chimie in Sisteron. He then became Industrial Director for Sanofi in the United Sates, followed by an appointment as Vice President of Supply Chain.
Jose Barella	Mr. Jose Barella has been Senior Vice President - Animal Health and Member of the Global Leadership Team of Sanofi SA since 2011. He holds a degree in Chemical Engineering from Escola de Engenharia Maua, Sao Paulo Brazil, and began his career in Chemical Engineering field with management positions with Alcoa and Cosipa Steel in Brazil. Before joining Merial in 2001 as Head of Companion Animals Global Enterprise and Head of Merial's Supply Chain, he spent over 20 years in global agriculture and life sciences industries, with Aventis Environmental Science (AES), Rhone-Poulenc Agriculture, and Rhone-Poulenc Rorer. While at AES, he was responsible for all operational/strategic aspects non-agricultural business of Aventis CropScience, including strategy, R&D, marketing, manufacturing, supply chain, finance and HR. Mr. Barella became Merial's Chief Operating Officer and Head of Business Operations in 2005, where he oversaw all commercial activities of the entire Merial product line globally, including sales and marketing and supply chain for the Companion Animal, Production Animal, Avian, Swine and Veterinary Public Health businesses. He was appointed Executive Chairman of Merial Limited in 2007.
Damian Braga	Mr. Damian Braga has been Senior Vice President - Vaccines Global Commercial Operations and Member of the Global Leadership Team of Sanofi SA since May 2011. He holds a degree in Economics from the University of Miami and an MBA degree in Finance from the Seton Hall University. Mr. Braga began his career with Sanofi Pasteur in 1988 as Financial Analyst. Over the next decade, he worked in a number of different functions within the Finance organization and served as the CFO from 1996 to 2001. In 2002, he was named President of the US Business Unit, and was involved in the launches of Menactra, Adacel and Pentacel. Mr. Braga was appointed to the position of President US, Vice President for Americas Region in 2007, which included leadership of the commercial operations in US, Canada and Latin America.
Jean-Francois Brin	Mr. Jean-Francois Brin has been Senior Vice President - Patient Centered Solutions and Member of the Global Leadership Team of Sanofi SA since October 2009. He is a Doctor of Medicine, holds a degree in Clinical Pharmacology & Toxicology and also is a graduate of HEC (Hautes Etudes Commerciales). In 1995, he started his career as Sales Representative and then he held various posts within the Marketing Division of Rhone-Poulenc Rorer, where he became Marketing Director Central Nervous System and Bone Metabolism. In 1999, he was appointed Sales Director in Cardio-Diabetes Business Unit in the French affiliate, subsequently becoming Cardio-Thrombosis Business Unit Head. Mr. Brin was appointed sanofi-aventis Thrombosis Franchise Head in 2004. In this post, he was responsible for defining long-term marketing and medical strategy and he chaired the Lovenox Strategic Steering Committee.
Pierre Chancel	Mr. Pierre Chancel has been Senior Vice President - Global Diabetes and Member of the Global Leadership Team of Sanofi SA as of September 2009. He was also Senior Vice President - Global Marketing & Access of Sanofi SA from August 2004 until September 2009. He is a graduate of the Institut de Pharmacie Industrielle Paris. At Rhone-Poulenc, from 1994 to 1996, he was Marketing Director for Theraplix. From 1997 to 1999, Mr. Chancel served as Business Unit Manager in charge of products in the central nervous system, rheumatology and hormone replacement therapy fields. From 2003, he served as Managing Director of Aventis Operations in the United Kingdom and Ireland. Before being appointed to this position, he was in charge of global strategy development at Aventis.
Michel DeWilde	Mr. Michel DeWilde, Ph.D., has been Senior Vice President - R&D Sanofi Pasteur and Member of the Global Leadership Team of Sanofi SA since 2001. He is a graduate of the Universite Libre de Bruxellles (ULB). In 1977, he started his career in the vaccine industry as a scientist at what is now GlaxoSmithKline Biologicals. He held various positions and was then named Vice President of R&D in 1993. In 1999, he joined what is now Sanofi Pasteur to head North America R&D and his responsibilities were extended to global vaccine R&D in 2001, overseeing the development and registration of a number of vaccines in the US and globally. He was involved in the acquisition of Acambis and Vaxdesign.
Gregory Irace	Mr. Gregory Irace has been Senior Vice President - Global Services and Member of the Global Leadership Team of Sanofi SA as of July 2011. He previously served as Senior Vice President - Pharmaceutical Operations, United States & Canada and Member of the Management Committee of Sanofi SA from February 2007 to July 2011. He holds a Bachelor of Science degree in Accounting from the Albany State University (State University of New York at Albany). He started his professional career at Price Waterhouse in 1980, where he held various positions for 11 years, including Director of Audit as of 1988, Director of Finance Department as of 1989. In 1991, he joined Sterling Winthrop Inc. as Regional Controller and in 1993 he became Director of Financial Planning and Analysis for Sanofi Winthrop L.P. From October 1994 to January 2007, he was Chief Financial Officer of Sanofi's Pharmaceutical Operations in the United States, most recently serving as Senior Vice President, Finance and Administration and Chief Financial Officer of sanofi-aventis US.
Marie-Helene Laimay	Ms. Marie-Helene Laimay has been Senior Vice President - Audit and Internal Control Assessment and Member of the Global Leadership Team of Sanofi SA since August 2004. Previously, Ms. Laimay was Senior Vice President - Director of Finance of the Company from May 2002 to August 2004. In November 2000, she assumed the function of Vice President - Internal Audit at the Company. She has a degree in Business from a French business school (Ecole Superieure de Commerce et d'Administration des Entreprises) and a DECS (an Accounting qualification). She spent three years as Auditor with Ernst & Young before joining Sanofi in 1985. Ms. Laimay served in a variety of financial positions, including Financial Director of Sanofi's beauty division and Deputy Financial Director of Sanofi-Synthelabo following the merger with Synthelabo in 1999.
Christian Lajoux	Mr. Christian Lajoux has been Senior Vice President & President Sanofi France, Member of the Global Leadership Team at Sanofi SA since June 2009. He previously served as Senior Vice President - Pharmaceutical Operations in France for the Company as of August 2004. Before this, he was Senior Vice President - Europe of the Company between January 1, 2003 and August 2004. Previously, he became Senior Vice President - France of Sanofi SA in 1999, the function he held until January 1, 2003. He has a degree (DEUG) in Psychology, a Bachelor degree in Philosophy and a post-graduate degree (DESS) in personnel management from the Institut d’Administration des Entreprises (IAE - Paris). He served in a variety of positions at Sandoz, including Division Director, before joining Sanofi Winthrop in 1993. He then served in various positions, including Director of Operations and Managing Director of Sanofi Winthrop France, before being appointed Senior Vice President for France just prior to the merger with Synthelabo in 1999. He was appointed as Chairman of Leem (Les entreprises du medicament) in July 2006. Since 2008, he has been President of the sanofi-aventis French Strategic Committee.
Gilles Lhernould	Mr. Gilles Lhernould has been Senior Vice President - Corporate Social Responsibility and Member of the Global Leadership Team of Sanofi SA as of October 2009. He previously served as Senior Vice President of Human Resources, Member of the Executive Committee of the Company from September 2008. Prior to that, he was Senior Vice President - Industrial Affairs, Member of the Executive Committee from December 1, 2007 to September 2008. In August 2004, Mr. Lhernould assumed the function of Senior Vice President - Industrial Affairs. He holds a diploma in Pharmacy and a Masters degree (DEA) in Industrial Pharmaceutics. He began his career as Manufacturing Supervisor at Laboratoires Bruneau, and in 1983 joined one of Sanofi’s subsidiaries where he managed production and later the factory. Mr. Lhernould then served in a variety of positions within the Sanofi Group, including Director of Human Resources - Pharmaceuticals for Sanofi Pharma and Director of Operational Human Resources for Sanofi. Following the merger with Synthelabo, he served as Vice President for integration, and then Vice President of Information Systems before being named Senior Vice President Industrial Affairs for Sanofi-Synthelabo in 2001. In 2004, he was appointed Senior Vice President, Industrial Affairs, sanofi-aventis.
Jean-Luc Lowinski	Mr. Jean-Luc Lowinski has been Senior Vice President - Asia Region, Vice President, Greater China Global Operations and Member of the Global Leadership Team of Sanofi SA, effective as of May 1, 2012. He holds a Doctorate in Philosophy degree in Veterinary Science from the Universite de Nantes, France and is a graduate from INSEAD or Institut Europeen d'Administration des Affaires, France. He joined Bayer Germany in 1992 and held various positions, including Head of Operations in Singapore, India, Thailand, China and Japan. In 2003, he became Head of Bayer Healthcare, China, before being appointed Head of Bayer Healthcare, Asia Pacific, and President, Bayer Yakuhin, Japan in 2007. Since 2010, he has been Global Head of the Animal Health Division at Bayer.
Heraldo Marchezini	Mr. Heraldo Marchezini has been Senior Vice President - Latin America Region, General Manager - Brazil Global Operations and Member of the Global Leadership Team of Sanofi SA since January 2011. He obtained a degree in Business Administration from Fundacao Getulio Vargas and earned a degree in Marketing from Escola Superior de Propaganda e Marketing - ESPM (Sao Paulo, Brazil). Mr. Marchezini started his career in 1988 at Rhone-Poulenc Polymer unit and moved to Rhone-Poulenc Rorer in 1993 where he held several sales and marketing positions, including OTC and hospital sales in the Brazilian affiliate. In 1996, he became Hospital Sales Manager and later led the Hospital & Oncology business in Aventis until early 2001, when he was appointed General Manager for Poland and Baltic countries, based in Poland. In 2004, he was appointed General Manager for the Brazilian subsidiary of Sanofi-Aventis.
Jez Moulding	Mr. Jez Moulding has been Senior Vice President - Japan & Pacific Region and General Manager - Japan, Member of the Global Leadership Team of Sanofi SA since January 2011. He holds a Master of Arts degree in Politics, Economic and Social History from the University of Edinburgh and a Graduate Diploma of Marketing from the Chartered Institute of Marketing in the UK. In 1991, he started his career in the UK as Sales Representative with Astra, holding a number of posts within the sales and marketing division. He joined the group in 1998 as the UK Cardiovascular Marketing manager and was appointed to various positions in the UK and the European Region. From 2002 to 2010 he has held four General Manager positions in South Africa, Korea, Australia and Japan.
Antoine Ortoli	Mr. Antoine Ortoli has been Senior Vice President - Intercontinental Global Operations and Member of the Global Leadership Team of Sanofi SA since January 4, 2005. He is a graduate of the Ecole Superieure de Commerce de Rouen, France, and of INSEAD. He also holds a Law degree and an Accountancy qualification. He began his career in 1980 as Financial and Systems Auditor with Arthur Young and Co. In December 1981, he joined the Sanofi Group, where he served in a variety of positions, including Finance Director of the Pharmaceuticals Division and Director of the Latin America region. Following the merger with Synthelabo in 1999, he was named Vice President of Latin America, and then Senior Vice President of Asia Middle East in June 2001. In June 2003, he took on the role of Vice President of Intercontinental region at Sanofi-Synthelabo.
Philippe Peyre	Mr. Philippe Peyre has been Senior Vice President - General Secretary and Member of the Global Leadership Team of Sanofi SA as of August 2004. He is a graduate of the Ecole Polytechnique, and began his career in management consultancy with Bossard before being appointed Member of the Executive Committee of Bossard Gemini Consulting. In 1998, he joined Rhone-Poulenc Rorer as Senior Vice President of Special Projects, and then served as Head of Integration at Aventis Pharma, and as Company Secretary and Senior Vice President of Business Transformation of Aventis.
Debasish Roychowdhury	Mr. Debasish Roychowdhury has served as Senior Vice President - Global Oncology and Member of the Global Leadership Team of Sanofi SA since August 2009. He received his medical training and a Doctorate of Medicine degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, and then moved to the United States in 1989 to specialize in internal medicine, hematology and oncology (at the University of California at San Francisco), and subsequently taught at the Faculty of Mecinine of the University of Cincinnati, where he directed a number of clinical programs. In 1999, he moved to Eli-Lilly's R&D Department to work in Oncology Clinical Research and later in Regulatory Affairs, and was appointed Vice President for Clinical Development at GlaxoSmithKline in 2005. In 2008, he was part of the team that created GSK's new Oncology R&D Unit, uniting all of the teams working on the subject.
Jean-Philippe Santoni	Mr. Jean-Philippe Santoni has been Senior Vice President - Industrial Development and Innovation and Member of the Global Leadership Team of Sanofi SA since June 2009. He holds a Doctorate in Medicine degree and a Masters degree in Human Biology. He started his career running a clinical and biological activity in various hospitals in Paris, and from 1985, he held various positions in charge of international clinical development and medical and regulatory affairs with Servier, then American Cyanamid/Lederle. He joined Synthelabo in 1990 as International Medical Director. Following its merger with Sanofi in 1999, he served successively as Associate Vice President Medical and Regulatory Affairs, Vice President International Clinical Operations and Vice President International Clinical Development, a position he retained after the merger with Aventis in 2004. In 2007, he was appointed Senior Vice President, International Development, R&D.
Laure Thibaud	Ms. Laure Thibaud has been Senior Vice President - Corporate Communications, and Member of the Global Leadership Team of Sanofi SA since June 2, 2009. Ms. Thibaud started her career as Public Relations Consultant before working for Alain Afflelou as Communication Manager. In 1990, she joined the GSK Group, where she remained for 17 years during which she held the following positions: in France, Head of Public Relations and Director of Communications; in London, Vice President Communications Europe; and in Brussels, Vice President External Affairs Europe. From 2007, Ms. Thibaud was global Executive Vice President Communications and Sustainable Development of the Axa Group.
Paul Chew	Dr. Paul Chew has been Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs and Member of the Global Leadership Team of Sanofi SA as of January 1, 2013. Dr. Chew was appointed Senior Vice President - Chief Medical Officer/Chief Scientific Officer US and Member of the Global Leadership Team of the Company in January 2009. Between 2007 and 2009, Dr. Chew held the position of President, US Research & Development and Vice President, Therapeutic Department Head, Metabolism, Diabetes and Thrombosis, responsible for Lovenox, Lantus, and the therapeutic development portfolio. Between 2001 and 2004, Dr. Chew was Vice-President, Global Head of Metabolism and Diabetes at Aventis Pharmaceuticals. He held numerous positions at Bristol-Myers Squibb between 1992 & 2001, including Vice President, US Medical Affairs (1999-2001). Prior to joining the industry, Dr. Chew was Assistant Professor of Medicine at The Johns Hopkins Hospital, Attending Physician in Radiology, Director of the Pacemaker Clinic and Member of the Interventional Cardiology staff. Dr. Chew obtained his degree in Medicine at The Johns Hopkins School of Medicine (Johns Hopkins University). He is Board-Certified in Internal Medicine and Cardiovascular Diseases. He is also Member of the PhRMA Science & Regulatory Affairs Executive Committee and the Institute of Medicine Value & Science-Driven Healthcare Roundtable.
Bruno Menard	Mr. Bruno Menard has been Chief Information Officer and Member of the Global Leadership Team of Sanofi SA since August 2011. He graduated from a French business school (Ecole Superieure de Commerce de Lille). He holds a Masters degree in Finance from the Universite Lille Nord de France and a professional degree in Accounting. Mr. Menard began his career at Sanofi in 1987. He served in a variety of financial positions in France and the United States, became General Manager first in Singapore in 1994, then in the Philippines in 1995. In 1998, he joined Sanofi Winthrop France as Director of Resources. In 2001, Mr. Menard was appointed Director, Information Systems for Sanofi-Synthelabo, then Vice President, Information Systems for sanofi-aventis in 2004.
Dante Beccaria	Mr. Dante Beccaria has been Vice President, Global Compliance Officer and Member of the Global Leadership Team at Sanofi SA since April 1, 2012. He holds a Degree in Economics from the University of Pavia (Italy). He began his career in 1985 in the field of Financing & Treasury and bank relationships first at Shell Italy and then Alcatel Italy. Mr. Beccaria has over 20 years' experience within Sanofi, having covered both operational and Corporate responsibilities. In 1990, he joined the Sanofi Italian affiliate to implement a Treasury Platform, gathering all the Business activities in the country. In 1992, he was appointed Controlling Director of the Italian Pharma affiliate. In 1997, he moved to Paris to take global responsibilities as Pharma Controller at Sanofi Corporate, then as CFO of the OTC & Generics Division. In 2001, he became Projects Director within the Mergers & Acquisitions Corporate department. In 2003, he joined the Corporate Internal Audit as Associate Vice President. He was then appointed Vice President Internal Audit after the acquisition of Aventis.
Thierry Vernier	Mr. Thierry Vernier has been Vice President - Plan & Financial Control, Member of the Global Leadership Team of Sanofi SA since January 2011. He is a graduate of ESC Le Havre-Caen, now Ecole de Management de Normandie and holds a Diploma in Accounting and Finance (DESCF). He began his career as an external auditor for KPMG in 1990, later becoming Deputy Controller of Coflexip Stena Offshore. He joined Sanofi SA in 1996 as Consolidation Director, and became successively Finance and Administration Director for Nordic countries and the United Kingdom. He held various Senior Corporate Finance functions since 2004, including Vice President, Financing and Treasury before becoming Vice President, Plan & Financial Evaluation in 2009.
Sebastien Martel	Mr. Sebastien Martel has been Vice President - Investor Relations and Member of the Global Leadership Team of Sanofi SA since September 1, 2008. He holds a Doctorate in Pharmacy, a Masters in Pharmaceutical Marketing Management, as well as an MBA from INSEAD or Institut Europeen d'Administration des Affaires, France. Previously, he was International Marketing Director at Novo Nordisk. Prior to Novo Nordisk, he was Vice President, Investor Relations at Serono. At Serono, he previously had global strategic marketing responsibility for the Reproductive Health portfolio. Before joining Serono, he was Marketing Director with Fournier in Canada, after holding several product management positions.
Francois Beloeuvre	Mr. Francois Beloeuvre is Vice-President - Strategy Industrial Affairs, Member of the Global Leadership Team of Sanofi SA. He is a graduate of ESSEC Business School (Ecole Superieure des Sciences Economiques et Commerciales) and a Certified Public Accountant. He started his career as a consultant for Arthur Andersen, where he became Partner in 1998 and latter served as Managing Director for BearingPoint from 2003 to 2009. In his consulting career, he has been involved in Automotive and FMCG industries leading transformation programs as well as pre and post integration projects. Mr. Beloeuvre joined Sanofi in February 2009. As Vice President of Strategy Industrial Affairs, he is leading a team coordinating the Industrial Affairs Long Range Plan and sourcing, interfacing with Business Development and managing some transformation programs in Industrial Affairs such as, Lean management, Energy and Innovation awards.
Thierry Bourquin	Mr. Thierry Bourquin has been Vice President, Chief Quality Officer and Member of the Global Leadership Team of Sanofi SA since July 2009. He is a Pharmacist and graduated in Biology and Drug Product Control. After serving in Hospitals and at Paris University, he held several positions in Analytical Development, Quality, and Manufacturing in Pharmaceutical Industry (Pfizer, Rhone-Poulenc Rorer, and Aventis). At European level, he was an expert of the European Pharmacopoeia and member of the Quality Ad Hoc group of EFPIA. In 1994, he was elected member of the French National Academy of Pharmacy. From 2001 to 2011, Mr. Bourquin served as Chairman of the Quality Committee of LEEM. He joined Sanofi-Synthelabo in 2001 as Head of Industrial Quality and Compliance. In 2004, he took the lead of Global Quality Industrial Operations for sanofi-aventis.
Jean-Philippe Collin	Mr. Jean-Philippe Collin has been Vice President - Procurement and Member of the Global Leadership Team of Sanofi SA since April 2010. He obtained a degree in Electrical Engineering from Ecole Superieure d'Electricite (Supelec), a PhD degree in Physics and started his career at IBM in 1982. He has held several executive positions in the areas of technology, quality and Procurement at IBM, Valeo & Thomson. In 2004, he joined PSA Peugeot Citroen as Chief Procurement Officer, and subsequently served as CEO of the Two-wheels Division, then as General Manager of the Peugeot brand in addition to being appointed on the executive Board of PSA.
Robert DeBerardine	Mr. Robert DeBerardine has been Vice President, Head of Global Patent Department and Member of the Global Leadership Team of Sanofi SA since 2011. He is responsible for all aspects of Sanofi's patent procurement strategies and patent litigation. He previously served as Chief Patent Counsel for Abbott Laboratories (2004-2008) and Assistant Chief Patent Counsel for Johnson & Johnson (2002-2004). He also worked as a trial attorney litigating patent cases when he was a partner at the law firms of Brobeck, Phleger and Harrison (1991-2002) and earlier with the law firm of Jones Day, Reavis and Pogue (1983-1990). He joined Sanofi in March 2008. He holds a Bachelors Degree in Chemical Engineering cum laude from Lafayette College and a Juris Doctor Degree magna cum laude from Cornell Law School (Cornell University).
Edward Greissing	Mr. Edward (Ed) Greissing is Vice President - US Corporate Affairs, Global Services; Member of the Global Leadership Team of Sanofi SA. He joined the Sanofi Group in 2006 and is responsible for the Company's Chronic Disease Prevention and Wellness Program, Health Innovation, Academic and Scientific Affairs, Federal and State government relations, public policy, reimbursement, global institutional relations, regional and local alliance development, patient advocacy, civic action, and corporate social responsibility. Prior to joining Sanofi US, he was President and CEO of Red Line Associates, a consulting firm with clients from the biopharmaceutical, device, food service and financial industries. For the 25 years before he established Red Line, he built a business-focused global government affairs organization for Upjohn which eventually became Pharmacia.
Jorge Insuasty	Mr. Jorge Insuasty, M.D., has been Vice President, Deputy of President R&D, Development and Member of the Global Leadership Team of Sanofi SA since July 2011. He graduated from the Universite Paris V Rene Descartes specializing in Cardiology and began his career as a hospital practitioner in Cardiology in France. Prior to joining Sanofi, he was Global Head Neuroscience and Ophthalmology Development Franchise, at Novartis in Basel Switzerland, where he was responsible for overall strategy, portfolio management and project execution. He was a member of the Development Leadership Team. Previous to this role, he was Global Head of Research and Development for Novartis OTC. From 1990 to 2003, he held various positions of increasing responsibility with Bristol Myers Squibb, leading functions and teams in Cardiovascular, Analgesia, Rheumatology development.
Andrew Plump	Mr. Andrew S. Plump has served as Vice President, Research & Translational Medicine and Deputy to the President of Global R&D and Member of the Global Leadership Team of Sanofi SA since July 2012. He received a Doctorate of Medicine (M.D.) degree from the University of California, San Francisco and obtained a Doctorate in Philosophy (Ph.D.) degree in Cardiovascular Genetics from The Rockefeller University. He also earned a Bachelor of Science degree (B.S.) from the Massachusetts Institute of Technology. He completed a residency in Internal Medicine and a Fellowship in Medical Genetics at U.C.S.F. Following his clinical training, he trained as a Howard Hughes postdoctoral fellow with Dr. Marc Tessier-Lavigne in the department of Anatomy and Neuroscience at U.C.S.F., after which he assumed faculty responsibilities as an Adjunct Clinical Instructor in the department of Medical Genetics. Mr. Plump joined Sanofi SA after eleven years in the pharmaceutical industry where he held various positions at Merck, initially as Director in the Department of Clinical Pharmacology and subsequently in Clinical Molecular Profiling and subsequently as Vice President and head of translational medicine and discovery in the Cardiovascular Disease Franchise. In the Cardiovascular Franchise at Merck Andrew was responsible for the Merck Cardiovascular Early Development, Translational Medicine and Discovery portfolios. In this role, he led the discovery and advancement of several programs in the Merck portfolio.
Maya Said	Dr. Maya R. Said has been Vice President - Strategy, External Innovation & Science Policy, Global R&D; Member of the Global Leadership Team of Sanofi SA since December 2011. She holds two Bachelor of Science degrees in Electrical Engineering & Computer Science and in Biology, a Master of Science degree in Toxicology, a Master of Engineering degree in Electrical Engineering & Computer Science, as well as a Doctor of Science degree in Electrical Engineering, Computer Science and Systems Biology, all from the Massachusetts Institute of Technology (MIT). Before joining Sanofi in 2011, she spent seven years at The Boston Consulting Group where she was a core member of BCG's HealthCare and Strategy practice areas, and held a number of research and teaching positions at MIT in the fields of computational biology and signal processing.
Martin Siewert	Mr. Martin Siewert has been Vice President Industrial Affairs - Injectables, President - Germany and Member of the Global Leadership Team of Sanofi SA since 2008. He joined the Company in 2005 as President for Germany. Mr. Siewert, a pharmacist, received his pharmaceutical education and a Doctorate of Medicine degree from the Universitat Frankfurt am Main, Germany. From 1981 till 1992, he held different positions at the Central Laboratory of German Pharmacists. He joined Hoechst 1992 in R&D. In 1995, he led the Hoechst-Marion-Roussel merger. In HMR and Aventis he served as SVP Quality Operations and EHS. In 2002, he moved to SVP Product Development and Supply.
Elias Zerhouni	Dr. Elias Zerhouni, M.D., has served as President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team of Sanofi SA as of January 1, 2011. In February 2009, Sanofi named Dr. Zerhouni, M.D., Scientific Advisor to Chief Executive Officer and to Senior Vice-President Research & Development. He received his basic education and training in Algeria, and his academic career was spent at the Johns Hopkins University and Hospital where he is currently Professor of Radiology and Biomedical Engineering and Senior Adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health of the United States of America from 2002 to 2008. He has authored over 200 publications, holds eight patents and has founded or co-founded five start-up companies. Dr. Zerhouni, M.D., holds a number of positions on Boards, including most recently, Senior Fellow of the Bill and Melinda Gates Foundations, the board of trustees of the Mayo Clinic and the Lasker Foundation. He earned membership into the Institute of Medicine of the US National Academy of Sciences in 2000 and received the Legion of Honor medal from the French National Order in 2008. He was appointed as Chair of Innovation at the College de France and elected to membership at the French Academy of Medicine in 2010. He also received the Transatlantic Innovation Leadership award in December 2011.
Dominique Carouge	Mr. Dominique Carouge has been Vice President - Administration & Management, Global R&D and Member of the Global Leadership Team of Sanofi SA since September 2011. He is a graduate from Reims Management School (a French business school) and also holds a Certified Public Accountant degree. From 1985 to 1991, he worked as an auditor with Ernst & Young in France and in the United States. In 1991, he joined Roussel Uclaf where he upheld a series of progressive financial positions. In 1996, he was appointed Chief Financial Officer for Hoechst Marion Roussel in Australia. From 1999 to 2002, he was in charge of Business Planning and Reporting at Aventis Pharma in Frankfurt, Germany. In 2003, he was appointed Operations Controller for the Aventis Group. In 2005, Mr. Carouge became Chief Financial Officer for the Vaccines division. Since 2009, he has served as Chief Strategy and Financial Officer for Sanofi Pasteur.
Peter Guenter	Mr. Peter Guenter is Executive Vice President in charge of Global Commercial Operations and a Member of the Executive Committee of Sanofi SA as of July 1, 2013. He is also a Member of the Company's Global Leadership Team and previously served as Senior Vice President - Europe Global Operations of Sanofi SA from July 2011. He holds a Masters Degree in Physical Education at the Faculty of Medicine and Health Sciences, University of Ghent, Belgium. He started his career in Sales at SmithKline in 1986. He joined the Group in 1995 and held various positions in France, Europe and Global Marketing. In 2000, he was appointed General Manager Belgium and then Vice President for Eastern Europe, Northern Europe & Scandinavia. In 2008, he was appointed General Manager, Commercial Operations for Germany, and in 2011, he was General Manager for the Multi-Country- Organisation for Germany, Switzerland and Austria.
David-Alexandre Gros	Mr. David-Alexandre Gros, M.D., has been Chief Strategy Officer, Member of the Executive Committee and the Global Leadership Team of Sanofi SA as of September 1, 2011. He worked in clinical and health outcomes research at the Department of Urology of the Johns Hopkins Hospital from 1996 to 1999, and then as Resident Physician at the University of Pennsylvania Health System from 1999 to 2000. In 2002, he joined McKinsey & Company's Pharmaceuticals & Medical Products practice as an Associate, and was promoted to Engagement Manager in 2004, and to Associate Principal in 2006. In late 2006, he joined Merrill Lynch as Vice President in Healthcare Investment Banking focusing on strategy, mergers & acquisitions and corporate finance until joining Centerview Partners in mid-2009 as Principal and Founding Member of the Healthcare Investment Banking Division. He obtained a Bachelor of Arts degree from the Dartmouth College in 1995, a Doctorate of Medicine from the Johns Hopkins University in 1999. He also received a Masters of Business Administration degree from the Harvard Business School in 2002.
David Khougazian	Mr. David Khougazian has been Head of the Office of the Chief Executive Officer and Member of the Global Leadership Team of Sanofi SA since January 2011. He is a graduate of ENSAE (Ecole Nationale de la Statistique et de l'Administration de l'Economie (ENSAE)), the national aeronautical and space engineering school, and holds an MBA degree from the College des Ingenieurs. After four years at CCF, a French bank, as financial engineer in Capital Market and fund manager in the Asset Management group, he joined Rhone-Poulenc in 1997 where he held a number of roles in Finance and then Business Development, including Vice President Mergers & Acquisitions for Aventis: the combination of Rhone-Poulenc and Hoechst. Following the creation of Sanofi-Aventis in 2004, he pursued his career in sales and marketing and was appointed as General Manager for Adriatics in 2008.
Anne Whitaker	Ms. Anne Whitaker has been President - North America, Pharmaceuticals and Member of the Global Leadership Team at Sanofi SA since September 2011. She holds a Bachelors degree in Chemistry and Business Administration from the University of North Alabama. She began her career at Delta Communications and joined the Upjohn Company in 1991 as a metabolic disease specialist. She joined GlaxoSmithKline in 1992 as a sales representative and held various leadership positions in the Commercial Organization. In 2001, she became Vice President of Critical and Supportive Care, a Business Division based in Pennsylvania, before being appointed Senior Vice President of Leadership and Organization Development, based in London, England, from 2008 to 2009. Since 2009, Ms. Whitaker was Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology at GlaxoSmithKline.
Ji Zhang	Mr. Ji Zhang has been Head of R&D Scientific Platforms and Member of the Global Leadership Team of Sanofi SA since July 2011. He is also Head of Clinical Sciences and Operations. He holds a Bachelor of Science degree and a Master of Science degree in Mathematics, Probability and Statistics from Beijing University, China. He also earned a Doctorate in Philosophy (Ph.D.) in Statistics from North Carolina State University, USA. Before joining Sanofi in 2003 as Head of Biostatistics and Programming, he was Senior Director, Clinical Biostatistics, at Merck Research Laboratories. He was appointed as Vice President, International Clinical Operations in 2007.
Laurent Attal	Mr. Laurent Attal has been Director of Sanofi SA as of May 4, 2012. He is also Member of the Strategic Committee of the Company. Additionally, he has been Executive Vice-President Research and Innovation at L'Oreal since January 2010. He serves as Director of Fondation d'Entreprise L'Oreal. Mr. Attal joined L'Oreal in 1986 in France as Sales Representative. Over the next several years, he held various positions within the Active Cosmetics division and was appointed CEO of Vichy in 1994. Four years later, Mr. Attal was named President of the Active Cosmetics division, with brands including Vichy, La Roche-Posay and Inneov, L'Oreal / Nestle joint venture of Nutricosmetics. In 2002, Mr. Attal became Member of the Executive Committee of L'Oreal and also oversaw the activities of the pharmaceutical company Galderma, the joint-venture between Nestle and L'Oreal. In 2005, he was appointed President and CEO of L'Oreal USA. He obtained a Doctorate of Medicine in Dermatology from the Faculty of Medicine in Paris (Faculte de Medecine de Paris), and holds a Masters of Business Administration degree from the INSEAD.
Thierry Desmarest	Mr. Thierry Desmarest has been Director of Sanofi SA since February 21, 2000 and is also Member of the Company's Remuneration Committee, Nominating and Governance Committee and Strategy Committee. Additionally, he is also Honorary Chairman and Director, Chiarma of the Nomination and Governance Committee, as well as Member of the Remunerations and Strategic Committees of Total SA, Director of Air Liquide, Renault SA, Renault SAS, Bombardier Inc and Musee du Louvre, among others. Since 1981, Mr. Desmarest has held various positions at the Total group, including Chairman and Chief Executive Officer (1995-2007) and Chairman of the Board from February 14, 2007 until May 2010. Until 2010, he was also Member of the Supervisory Board of Areva. He graduated from the Ecole Polytechnique de Paris in 1966 and from the Ecole Narionale Superieurs des Mines de Paris (Ecole des Mines de Paris in 1970).
Igor Landau	Mr. Igor Landau has been Director of Sanofi SA as of August 2004. He is also Director of INSEAD, Member of the Supervisory Boards of Allianz AG and Chairman of the Supervisory Board of Adidas-Salomon. Until 2012, he was Director of HSBC France, among others. Mr. Landau previously served as Chief Executive Officer of the German subsidiary of La Compagnie du Roneo from 1968 to 1970, Management consultant at McKinsey in France from 1971 to 1975, and then held until 2004 various positions at the Rhone-Poulenc group, including member of the Management Board of Aventis (1999-2002) and Chairman of the Management Board of Aventis (2002-2004). Between 2001 and 2005, he was a Director of Essilor, and he also served as Director of Thomson (now called Technicolor) from 2002 to 2005 and as Member of the Supervisory Board of Dresdner Bank from 2003 to 2006. Mr. Landau obtained a degree from the Hautes etudes commerciales (HEC) and holds an MBA from the INSEAD.
Christian Mulliez	Mr. Christian Mulliez has been Director of Sanofi SA since June 2004. He is also Member of the Audit and Remuneration Committees of the Company. Additionally, Mr. Mulliez serves as Chairman of the Board of Regefi, and Director of DG 17 Invest, L'Oreal USA Inc., Galderma Pharma and of The Body Shop International. He has been Executive Vice Chairman and General Manager Administration and Finance at L'Oreal since 2003. Between 1984 and 2002, he held various positions at Synthelabo and then at Sanofi-Synthelabo, including Vice President Finance. Mr. Mulliez is a graduate from the Ecole Superieure des Sciences Economiques et Commerciales (ESSEC).
Uwe Bicker	Mr. Uwe Bicker has been Independent Director of Sanofi SA since May 14, 2008. He is also Member of the Strategy Committee of the Company. Additionally, he serves as Member of the Supervisory Board of Fondation Aventis and of Future Capital AG, as well as Member of the Consulting Committee of Morgan Stanley. As of 2011, he has been the Dean at the Medical Faculty of the Heidelberg University, where he has been Professor since 1983, and he also became Managing Director at the University Clinic of Mannheim in 2011. He is also an Honorary Senator of Heidelberg University and an Honorary Doctor of the Klausenburg University. During his professional career, Mr. Bicker was also appointed as Trustee of Fondation Aventis. Between 1975 and 1994, he held various positions at Boehringer Mannheim GmbH (later Roche AG) and from 1994 to 2004, he held various positions at Hoechst group. Until 2012, Mr. Bicker also served as Chairman of the Supervisory Board of Siemens Healthcare Diagnostics Holding GmbH, Vice Chairman of the Supervisory Board of Epigenomics AG and of Definiens AG. He is a Physician and holds a Doctorate in Chemistry and Medicine.
Robert Castaigne	Mr. Robert Castaigne has been Independent Director of Sanofi SA since May 4, 2012. He is also Member of the Audit Committee of the Company. Additionally, Mr. Castaigne serves as Director of Vinci and Societe Generale. He is also Member of the Audit, Internal Control and Risks Committee of Societe Generale, as well as Member of the Audit and Remuneration Committees of Vinci. Previously, he served as Director of Sanofi SA from February 21, 2000 to May 4, 2012. Until 2011, he held the posts of Director and Member of the Audit Committee of Compagnie Nationale a Portefeuille, among others. Between 1972 and 2008, he held various positions at the Total group, including Chief Financial Officer and Member of the Executive Committee (June 1994 to May 2008). He was also Chairman and Chief Executive Officer of Total Chimie (1996-2008) and of Total Nucleaire (1992-2008), amongst other positions. Mr. Castaigne holds a degree from the Ecole Centrale de Lille and the Ecole Nationale Superieure du Petrole et des Moteurs, and also holds a Doctorate in Economics from the Universite Paris I Pantheon Sorbonne.
Lord Douro	Mr. Lord Douro has been Independent Director of Sanofi SA since May 22, 2002. He is also Member of the Company's Nominating, Governance and Strategy Committees. Additionally, he acts as Chairman of Richemont Holdings UK Ltd and Kings College London, Director of Compagnie Financiere Richemont AG, GAM Worldwide and RIT Capital, as well as Member of the Nominating and Remunerations Committees of Compagnie Financiere Richemont AG, among others. Previously, Mr. Douro was Director and Member of the Remuneration and Nominating Committee of Pernod Ricard, as well as Director of Abengoa Bioenergy until 2011, among others. From 1979 to 1989, he served as Member of the European Parliament, from 1995 to 2000, as Chairman of Sun Life & Provincial Holdings Plc and from 1993 to 2005, as Chairman of Framlington Group Ltd (United Kingdom). Mr. Douro holds a Master of Arts degree from the University of Oxford.
Jean-Rene Fourtou	Mr. Jean-Rene Fourtou has been Independent Director of Sanofi SA since August 2004 and he is also Member of the Remuneration, Nominating and Governance Committees and of the Strategy Committee of the Company. He is also Chairman of the Supervisory Board of Vivendi and Member of the Supervisory Board of Maroc Telecom. He served as Director and Member of the Remunerations Committee of Nestle until 2012. Until 2010, he served as Director of NBC Universal Inc, among others. Mr. Fourtou previously held various positions at the Bossard group from 1963 to 1986, including Chairman and Chief Executive Officer (1977-1986). From 1986 to 1999, he was Chairman and Chief Executive Officer of Rhone-Poulenc; between 1999 and 2004, he was Vice Chairman of the Management Board, Vice Chairman of the Supervisory Board and Member of the Strategy Committee of Aventis; and from 2002 to 2005, he was Chairman and Chief Executive Officer of Vivendi. He also held various mandates, including Vice President then Member of the Supervisory Board of Axa from 1990 to 2009. Mr. Fourtou graduated from the Ecole Polytechnique de Paris in 1963.
Claudie Haignere	Ms. Claudie Haignere has been Independent Director of Sanofi SA since May 14, 2008. She is also Member of the Company's Nominating, Governance and Remuneration Committees. She is Chairman of the Board of La Geode and Chairman of Universcience (Cite des Sciences et de l'Industrie and Palais de la Decouverte), and holds various other mandates, including Director of France Telecom, Fondation de France, Fondation CGenial, Fondation d'Entreprise L'Oreal and Fondation Lacoste, among others. Ms. Haignere is a Certified Rheumatologist and holds a Doctorate in Science specialized in Neurosciences. She was selected in 1985 by CNES (French National Space Center) as a candidate astronaut. She worked as a Rheumatologist, Cochin Hospital (Paris), from 1984 to 1992, and took part in the Scientific space mission to the MIR space station (Cassiopee Franco-Russian mission) in 1996, and in the Technical and scientific space mission to the International Space Station (Andromede mission) in 2001. Between 2002 and 2004, she was the Deputy Minister for Research and New Technologies in the French government, and from 2004 to 2005, she served as Deputy Minister for European Affairs. Until 2011, she was Vice Chairman of IAA and Director of Aero Club de France, among others.
Suet-Fern Lee	Ms. Suet-Fern Lee has been Independent Director of Sanofi SA as of May 6, 2011. She has been Senior Partner of Stamford Law Corporation, Singapore since 2000. She also became President-Elect of the Inter-Pacific Bar Association (IPBA) in 2008. Since 2006, she has been Member of the Board of trustees of Nanyang Technological University, Member of the Accountant Advisory Board of the National University of Singapore Business School since 2006, as well as Member of the Advisory Committee of the Singapore Management University School of Law since 2007. Ms. Lee is also Chairman of the Board of the Asian Civilisations Museum, which is one of the National Museums of Singapore, and Director of the following companies: Axa, Macquarie International Infrastructure Fund Ltd, National Heritage Board, Rickmers Trust Management Pte Ltd and Stamford Corporate Services Pte Ltd. Ms. Lee obtained a degree in Law from the Cambridge University in 1980 and she qualified as a Barrister-at-Law at Gray's Inn London in 1981 before qualifying to the Singapore bar in 1982.
Carole Piwnica	Ms. Carole Piwnica has been Independent Director at Sanofi SA since December 15, 2010 and she has bee also Member of the Company's Audit Committee since December 13, 2011. Additionally, she serves as Director of Naxos UK Ltd, Eutelsat, Louis Delhaize, Big Red (United States), Elevance (United States) and Amyris Inc. She is also Director and Chairman of the Governance Committee of Eutelsat Communications. Ms. Piwnica started her professional career in 1985 at Proskauer Rose, New York, before joining the merger & acquisitions department of Shearman & Sterling, Paris, in 1987. She was General Counsel at Gardini et Associes from 1991 to 1994 when she joined Amylum Group where she was appointed Chairman in 1996 having previously served as Chief Executive Officer of Amylum France. In 1996, she was appointed Vice-president and Board Member of Tate & Lyle Plc. She also served as Director of Spadel (Belgium) from 1998 to 2004, Director and Vice-Chairman for Governmental Affairs from 2000 to 2006, Chairman of the Liaison Committee and director of the CIAA (Confederation of the Food and Drink Industries of the European Union) from 1996 to 2006, and Chairman of the Export Commission and director of the Association Nationale des Industries Alimentaires from 2000 to 2006. Until 2011 she was Director of Aviva Plc, among others. Ms. Piwnica holds a Juris Doctor degree from the Universite Libre de Bruxelles and a Masters in Law (Master of Legal Letters) degree from the New York University, and was admitted to the Paris and New York Bars.
Klaus Pohle	Mr. Klaus Pohle has been Independent Director of Sanofi SA since August 2004 and is also Chairman of the Audit Committee of the Company. He also serves as Member of the Supervisory Board of Fondation Aventis. Mr. Pohle was Chairman of the German Accounting Standards Board (GASB) from 2003 to 2005, Deputy Chief Executive Officer and Chief Financial Officer of Schering AG from 1981 to 2003, and held various positions at the BASF group from 1966 to 1980. He holds a Doctorate (Doctorate in Philosophy) degree in Law from the Frankfurt University (Johann Wolfgang Goethe-Universitaet Frankfurt am Main), a Doctorate (Doctorate in Philosophy) degree in Economics from the University of Berlin, a Masters degree in Law from the Harvard University, and is a Professor of Business Administration at the Berlin Institute of Technology.
Gerard Van Kemmel	Mr. Gerard Van Kemmel has been Independent Director of Sanofi SA since May 19, 2003. He is also Chairman of the Remuneration Committee and Member of the Audit, and Nominating and Governance Committees of the Company. He is also Director and Member of the Audit Committee of Europacorp. Until 2010, he was Director of Eurotunnel NRS Holders Company Limited and of Eurotunnel Group. Between 2004 and 2006, he served as Chairman of Novell for Europe. From 2008 to 2010, he was Director of Groupe Europtunnel. Between 1966 and 1995, he held various positions, including President of Arthur Andersen and Andersen Consulting in France (1976-1995) and Chairman of the Board of Arthur Andersen Worldwide (1989-1994). From 1996 to 1997, he served as Senior Advisor to the French Finance Minister and then, between 1996 and 2006, he held various positions at Cambridge Technology Partners (Chief Operating Officer) and at Novell (President EMEA). Mr. Van Kemmel obtained a degree from the Ecole des Hautes Etudes Commerciales (HEC) and holds an MBA degree from the Stanford Business School.

Basic Compensation

Name	Fiscal Year Total
Serge Weinberg	709,463
Christopher Viehbacher	3,608,290
Jerome Contamine	--
David Meeker	--
Gary Nabel	--
Karen Linehan	--
Roberto Pucci	--
Olivier Charmeil	--
Philippe Luscan	--
Jose Barella	--
Damian Braga	--
Jean-Francois Brin	--
Pierre Chancel	--
Michel DeWilde	--
Gregory Irace	--
Marie-Helene Laimay	--
Christian Lajoux	--
Gilles Lhernould	--
Jean-Luc Lowinski	--
Heraldo Marchezini	--
Jez Moulding	--
Antoine Ortoli	--
Philippe Peyre	--
Debasish Roychowdhury	--
Jean-Philippe Santoni	--
Laure Thibaud	--
Paul Chew	--
Bruno Menard	--
Dante Beccaria	--
Thierry Vernier	--
Sebastien Martel	--
Francois Beloeuvre	--
Thierry Bourquin	--
Jean-Philippe Collin	--
Robert DeBerardine	--
Edward Greissing	--
Jorge Insuasty	--
Andrew Plump	--
Maya Said	--
Martin Siewert	--
Elias Zerhouni	--
Dominique Carouge	--
Peter Guenter	--
David-Alexandre Gros	--
David Khougazian	--
Anne Whitaker	--
Ji Zhang	--
Laurent Attal	50,000
Thierry Desmarest	90,000
Igor Landau	2,345,670
Christian Mulliez	92,500
Uwe Bicker	104,000
Robert Castaigne	105,000
Lord Douro	119,000
Jean-Rene Fourtou	1,776,790
Claudie Haignere	80,000
Suet-Fern Lee	79,000
Carole Piwnica	108,750
Klaus Pohle	146,500
Gerard Van Kemmel	140,000

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Serge Weinberg	0	0
Christopher Viehbacher	0	0
Jerome Contamine	0	0
David Meeker	0	0
Gary Nabel	0	0
Karen Linehan	0	0
Roberto Pucci	0	0
Olivier Charmeil	0	0
Philippe Luscan	0	0
Jose Barella	0	0
Damian Braga	0	0
Jean-Francois Brin	0	0
Pierre Chancel	0	0
Michel DeWilde	0	0
Gregory Irace	0	0
Marie-Helene Laimay	0	0
Christian Lajoux	0	0
Gilles Lhernould	0	0
Jean-Luc Lowinski	0	0
Heraldo Marchezini	0	0
Jez Moulding	0	0
Antoine Ortoli	0	0
Philippe Peyre	0	0
Debasish Roychowdhury	0	0
Jean-Philippe Santoni	0	0
Laure Thibaud	0	0
Paul Chew	0	0
Bruno Menard	0	0
Dante Beccaria	0	0
Thierry Vernier	0	0
Sebastien Martel	0	0
Francois Beloeuvre	0	0
Thierry Bourquin	0	0
Jean-Philippe Collin	0	0
Robert DeBerardine	0	0
Edward Greissing	0	0
Jorge Insuasty	0	0
Andrew Plump	0	0
Maya Said	0	0
Martin Siewert	0	0
Elias Zerhouni	0	0
Dominique Carouge	0	0
Peter Guenter	0	0
David-Alexandre Gros	0	0
David Khougazian	0	0
Anne Whitaker	0	0
Ji Zhang	0	0
Laurent Attal	0	0
Thierry Desmarest	0	0
Igor Landau	0	0
Christian Mulliez	0	0
Uwe Bicker	0	0
Robert Castaigne	0	0
Lord Douro	0	0
Jean-Rene Fourtou	0	0
Claudie Haignere	0	0
Suet-Fern Lee	0	0
Carole Piwnica	0	0
Klaus Pohle	0	0
Gerard Van Kemmel	0	0

Insider Trading

» Full list on Insider Trading

People: Sanofi SA (SNY)

Related Topics:

Summary

Biographies

Basic Compensation